Do antiphospholipid antibodies develop for a purpose?

Current Rheumatology Reports

Volumn 8, Issue 2, 2006, Pages 109-113

  Merrill, Joan T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; OXIDATION; PATHOGENESIS; REVIEW; T LYMPHOCYTE; VASCULARIZATION; IMMUNOLOGY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; IMMUNITY, NATURAL;

EID: 33646943343     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0050-2     Document Type: Review

References (26)

1. Czompoly T, Olasz K, Simon D, et al.: A possible new bridge between innate and adaptive immunity: Are the anti-mitochondrial citrate synthase autoantibodies components of the natural antibody network? Mol Immunol 2005, In press.
2. Baumgarth N, Tung JW, Herzenberg LA: Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 2005, 26:347-362. This review article summarizes current understanding of natural autoantibodies and their role in immune defense.
3. Chang MK, Boullier A, Hartvigsen K, et al.: The role of natural antibodies in atherogenesis. J Lipid Res 2005, 46:1353-1363. This paper suggests that natural autoantibodies might have complicated effects in the bloodstream, including a role in the pathogenesis of atherosclerosis.
4. Binder CJ, Silverman GJ: Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin Immunopathol 2005, 26:385-404.
5. Zohar Y, Wildbaum G, Karin N: Beneficial autoimmunity participates in the regulation of rheumatoid arthritis. Front Biosci 2006, 11:368-379.
6. McIntyre JA, Wagenknecht DR, Faulk WP: Redox-reactive autoantibodies: Detection and physiological relevance. Autoimmun Rev 2006, 5:76-83.
7. McIntyre JA: The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation-reduction reactions. Thromb Res 2004, 114:579-587. This paper elucidates some of the problems in the detection and understanding of antiphospholipid antibodies and provides data consistent with the hypothesis that they have binding characteristics in common with natural autoantibodies
8. Blank M, Asherson RA, Cervera R, Shoenfeld Y: Antiphospholipid syndrome infectious origin. J Clin Immunol 2004, 24:12-23. This paper contains important concepts in the understanding of how antiphospholipid antibodies might evolve from key host defense against infection.
9. Shovman O, Gilburd B, Barzilai O, et al.: Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci 2005, 1050:380-388.
10. Wananukul S, Voramethkul W, Kaewopas Y, Hanvivatvong O: Prevalence of positive antinuclear antibodies in healthy children. Asian Pac J Allergy Immunol 2005, 23:153-157.
11. Fields RA, Toubbeh H, Searles RP, Bankhurst AD: The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989, 16:623-625.
12. Shi W, Krilis SA, Chong BH, et al.: Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990, 20:231-236.
13. McIntyre JA, Wagenknecht DR, Faulk WP: Autoantibodies unmasked by redox reactions. J Autoimmun 2005, 24:311-317.
14. Stahl D, Hoemberg M, Cassens U, et al.: Influence of isotypes of disease-associated autoantibodies on the expression of natural autoantibody repertoires in humans. Immunol Lett 2006, 102:50-59.
15. Reipert BM, Tanneberger S, Pannetta A, et al.: Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? Cancer Immunol Immunother 2005, 54:1038-1042.
16. Yuste JR, Prieto J: Anticardiolipin antibodies in chronic viral hepatitis. Do they have clinical consequences? Eur J Gastroenterol Hepatol 2003, 15:717-726.
17. Asherson RA, Cervera R: Antiphospholipid antibodies and infections. Ann Rheum Dis 2003, 62:388-393.
18. Lee J, Cho YJ, Lipsky PE: The V(lambda)-J(lambda) repertoire of patients with systemic lupus erythematosus manifests characteristics of the natural antibody repertoire. Arthritis Rheum 2004, 50:2604-2614. This paper supports the hypothesis that pathologic autoantibodies might derive from an innate immune response that was originally in the interests of the host.
19. Quintana FJ, Cohen IR: The natural autoantibody repertoire and autoimmune disease. Biomed Pharmacother 2004, 58:276-281.
20. Djoumerska I, Tchorbanov A, Pashov A, Vassilev T: The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used. Scand J Immunol 2005, 61:357-363.
21. Lieby P, Poindron V, Roussi S, et al.: Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack. Blood 2004, 104:1711-1715.
22. Field SL, Brighton TA, McNeil HP, Chesterman CN: Recent insights into antiphospholipid antibody-mediated thrombosis. Baillieres Best Pract Res Clin Haematol 1999, 12:407-422.
23. Rauch J, Subang R, D'Agnillo P, et al.: Apoptosis and the antiphospholipid syndrome. J Autoimmun 2000, 15:231-235.
24. Languren M, Becerril B, Cabral AR, et al.: Characterization of monoclonal anti-beta(2)-glycoprotein-I and antiprothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome. J Autoimmun 2006, 26:57-65.
25. Rauch J, D'Agnillo P, Subang R, Levine JS: Antiphospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid-dependent interactions with apoptotic cells. Thromb Res 2004, 114:371-382.
26. Meroni PL, Raschi E, Testoni C, Borghi MO: Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004, 112:169-174.